View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Chapter 3.1<br />
128<br />
METHODS<br />
Study design<br />
Japanese academic hospitals and major general hospitals were invited to participate in<br />
the study. Additional entry criteria were availability of data on previous treatment with<br />
interferon and on clinical outcomes.<br />
All consecutive chronic hepatitis C patients who received interferon alpha treatment<br />
between January 1, 1990 and December 31, 1995 and who did not show a sustained<br />
virological response were included. Sustained virological response was defi ned as normal<br />
alanine aminotransferase (ALT) and negative HCV-RNA at the end of treatment and<br />
six months thereafter.<br />
The ethics committees of all participating centers approved the protocol. In order to<br />
ensure privacy of the patients, the treating physician replaced patient names by a code<br />
before entry in the database.<br />
Patient selection<br />
Data of all consecutive patients with chronic hepatitis C with non-response to previous<br />
interferon treatment were collected. Data were collected on separate case record<br />
forms, one per patient, by the local investigator. The case record forms were sent to the<br />
co-ordination center in <strong>Rotterdam</strong>, where the data were entered in a central database.<br />
Before the data were entered, they were checked and in case of doubt, contact was<br />
made with the local investigator.<br />
Data recorded<br />
Information was obtained on demographics (age, gender) and on details of the interferon<br />
treatment (starting date, duration, and total dose) as well as the glycyrrhizin treatment<br />
(starting date, duration, total dose). Virological data (genotype, viremia), hematological<br />
(platelet count) and biochemical data (aminotransferase levels, bilirubin, and gamma<br />
glutamyltransferase) were measured in the certifi ed laboratories of the participating<br />
hospitals and added to the case record form by the local investigator. Centrally, the<br />
results were corrected for local normal values.<br />
Follow-up data were recorded every four weeks if available and included ALT-levels, start<br />
of glycyrrhizin treatment and the occurrence of HCC. Patients were considered to have<br />
a HCC if biopsy proved so or if ultrasound or computed tomography showed a focal<br />
lesion in the presence of a serum alpha-fetoprotein of > 400.